Abstract 5914
Background
The case for investing in better integrated mental health provision and training in cancer care is compelling. Mental health co-morbidity in cancer and end of life care is very common, poorly recognized, and leads to distress and loss of functioning. The recent SMaRT oncology trials, (Walker et al., 2014) have demonstrated that up to 73% of cancer patients with depression receive no evidence-based treatment for their depression. Standardized mortality ratio (SMR) for completed suicide in the cancer patient is four to seven times that of the matched population, (Robinson et al., 2009; Robson et al ., 2010). The increased awareness of co-morbid mental health conditions have impacted upon and influenced the cancer world. Yet, despite the plethora of research and policy advocating for better mental health provision for cancer patients, there is still a lack of recognition of the importance of assessing and managing co-morbid mental health in cancer patients.
Methods
The authors designed a one-day simulation based training programme using trained actors portraying cancer journeys, from diagnosis to end of life, with a number of different and relevant mental health co-morbidities. Inter-professional participants (n = 75) filled questionnaires both before and after the intervention (the simulation programme). The questionnaires consisted of multiple choice questions assessing knowledge of mental health co-morbidity in the cancer patient, and confidence (self- rated 1-5 Likert scales).
Results
Statistical t test analysis of pre v post intervention scores (n = 75) revealed highly statistically significant imrpovements to participants’ clinical knowledge (p < 0.0001) and confidence (p < 0.0001) as a result of the simulation intervention.
Conclusions
This study demonstrates that an innovative simulation programme has been evaluated as highly effective in improving knowledge and confidence of inter-professional learners at managing mental health co-morbidity in cancer patients. More research in this educational modality is welcomed in training clinicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Fernando.
Funding
Health Education England.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract